Which Peptides Are Actually Safe to Take—and Which Should I Avoid?

A concierge physician reviewing lab results and a treatment plan with a patient in a Naples, Florida medical office

Peptide therapies now sit at the center of obesity medicine, bone health, and the broader longevity conversation—and for good reason. Many of the most important drugs in modern medicine are peptides. But the term covers a wide spectrum, from well-studied, FDA-approved treatments with years of clinical data to experimental compounds with no meaningful human evidence. For active adults over 50, understanding that difference is essential. 

 

Why These Distinctions Matter

The question is not whether peptides therapies are legitimate—it is whether a specific peptide e is appropriate for your health goals, medical history, and long-term care plan.  In adults over 50, a poorly chosen intervention does not just waste money. It can delay real treatment, introduce avoidable risk, and create a false sense of proactive care. For many adults, the goal is not simply just weight loss or symptom management—it’s preserving strength, mobility, energy, and independence for years ahead. 

 

Approved Weight-Loss Peptides Deliver Outcomes That Matter

GLP-1 receptor agonists represent the strongest evidence base in peptide medicine today. In the STEP 1 trial, semaglutide 2.4 mg produced a mean body weight reduction of 14.9% over 68 weeks in adults with overweight or obesity without diabetes (Wilding et al., 2021). The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in over 17,000 adults with preexisting cardiovascular disease and overweight or obesity (Lincoff et al., 2023). Tirzepatide achieved up to 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (Jastreboff et al., 2022) and received FDA approval in December 2024 as the first medication indicated for moderate-to-severe obstructive sleep apnea in adults with obesity (U.S. Food and Drug Administration, 2024). These outcomes matter because excess weight drives diabetes, hypertension, sleep apnea, joint deterioration, and cardiovascular disease—conditions that compound silently before becoming crises. 

Doctor’s Note: Weight on the scale is not the only metric worth tracking. GLP-1–based treatment should always include a plan for protecting lean tissue—resistance training and adequate protein intake are not optional. Patients who skip those steps can lose significant muscle alongside fat, which undermines long-term strength and mobility. 

 

Bone-Building Peptides Protect Against a Frequently Missed Risk

Bone loss rarely gets the attention it deserves, but an untreated fracture can be just as consequential as a cardiovascular event. Teriparatide is an FDA-approved parathyroid hormone analog for postmenopausal women and men with osteoporosis at high fracture risk, with randomized controlled trial evidence demonstrating reductions in vertebral and nonvertebral fractures (Neer et al., 2001).  In otherwise active adults, a hip fracture can trigger a cascade of deconditioning and loss of independence that is often difficult to reverse.. The Endocrine Society has noted that fractures in older adults are frequently unrecognized as osteoporosis-related, leaving many patients without treatment to prevent the next one (Cappola et al., 2023). Any low-trauma fracture warrants formal evaluation—not observation. 

 

Most Anti-Aging Peptides Have No Adequate Human Evidence

The Endocrine Society’s 2023 scientific statement is unambiguous: no therapy designed to increase growth hormone secretion or action is currently approved as an anti-aging intervention, and the risks may outweigh the benefits (Cappola et al., 2023). Compounds such as BPC-157, TB-500, CJC-1295, and ipamorelin are widely promoted for tissue repair, recovery, and performance. A 2025 review identified 36 preclinical studies and only one human trial on BPC-157; CJC-1295 without DAC has zero published human trials. The FDA placed BPC-157 and TB-500 on its Category 2 restricted list, prohibiting compounding pharmacies from producing them, citing immunogenicity and impurity concerns (U.S. Food and Drug Administration, 2025a). CJC-1295 and ipamorelin were removed from that list in September 2024 and remain under active FDA review. 

Doctor’s Note: When someone asks about a wellness peptide, the right first question is: how many people has this been studied in, and what did the data show? A compelling mechanism in an animal model is not clinical evidence—and patients deserve treatments held to that standard. 

 

Compounded GLP-1 Products Carry Documented Safety Risks

Compounded GLP-1 products do not undergo FDA review for safety, effectiveness, or quality before being marketed (U.S. Food and Drug Administration, 2025b). Some are counterfeit, contaminated, or formulated with unapproved salt forms. FDA had received more than 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide as of early 2025, many involving dosing errors requiring hospitalization. Brand-name semaglutide and tirzepatide are no longer on the FDA drug shortage list, removing the primary rationale for compounded alternatives. 

 

What to Do Next

  • Define the treatment goal before requesting any peptide. Weight management, cardiovascular risk reduction, sleep apnea, fracture prevention, or a confirmed endocrine disorder—a clinical indication is the starting point. 
  • Get baseline labs first: fasting glucose, HbA1c, lipid panel, and kidney function. These confirm whether an indication exists and set a baseline to track against. 
  • Screen for GLP-1 contraindications—especially personal or family history of medullary thyroid carcinoma or MEN2 syndrome, prior pancreatitis, gallbladder disease, and significant kidney impairment. 
  • Track lean tissue and strength every 8 to 12 weeks during GLP-1 therapy. Resistance training and adequate protein should be in place from day one, not added later. 
  • Treat any fragility fracture as a clinical event requiring bone density testing and a treatment discussion—not watchful waiting. 
  • Verify the source of any compounded peptide. A research-chemical label or online vendor without pharmacy documentation is a reason to stop, not proceed. 

 

The Standard That Protects Patients Over Time

Peptide therapy offers real clinical value when matched to a confirmed diagnosis, a clear outcome goal, and a physician who stays involved. A concierge physician brings the time, access, and continuity to evaluate individual risk, track the evidence, and adjust the plan before small problems become larger ones. For adults focused on long-term health, that personalized oversight is not a luxury—it is what prevention requires. At Naples Concierge Health, peptide therapy is never approached as a trend or one-size-fits-all solution. Every recommendation begins with a comprehensive approach and understanding of the patient. This includes their metabolic health, cardiovascular risk, lifestyle, long-term goals, and the treatments most likely to improve both quality and longevity of life. 

Visit www.naplesconciergehealth.com to learn more or make an appointment. 

To receive health insights, preventive medicine updates, and news from Naples Concierge Health directly in your inbox, sign up to join the newsletter.

 



Frequently Asked Questions About Peptide Therapy

1. What peptide therapies are FDA-approved and backed by strong clinical evidence?

FDA-approved peptides with the strongest human evidence include semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) for obesity and cardiometabolic disease, and teriparatide (Forteo) for osteoporosis at high fracture risk. Semaglutide is also approved for reducing cardiovascular events in adults with established cardiovascular disease and overweight or obesity, based on the SELECT trial. Tirzepatide is the first medication approved for obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials.

 

2. Are compounded peptides like BPC-157, CJC-1295, and TB-500 safe?

BPC-157 and TB-500 remain on the FDA’s Category 2 restricted list, which prohibits compounding pharmacies from producing them for human use due to immunogenicity and impurity concerns. CJC-1295 and ipamorelin were removed from Category 2 in September 2024 and are under active FDA review. None of these compounds has completed the phase 3 human clinical trials required for FDA approval. Adults considering any compounded peptide should confirm its current regulatory status and work with a physician who can appropriately evaluate safety and monitor therapy.

 

3. Is there any peptide therapy approved for anti-aging?

No. The Endocrine Society’s 2023 scientific statement explicitly states that no therapy designed to increase growth hormone secretion or action is approved as an anti-aging intervention, and the risks may outweigh the benefits. Growth hormone secretagogues and related compounds are widely marketed for anti-aging and performance but lack the clinical trial evidence required to support routine use in healthy older adults.

4. What are the risks of buying compounded GLP-1 medications online?

FDA had received over 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide as of early 2025, many involving dosing errors from multidose vials that required hospitalization. Online products may be counterfeit, contaminated, contain incorrect active ingredient forms, or be sold using “research use only” language to circumvent federal law. Brand-name GLP-1 medications are no longer on the FDA drug shortage list as of 2025.

5. How does a concierge physician in Naples approach peptide therapy?

A concierge physician begins with a confirmed clinical indication—established through comprehensive lab testing, hormone evaluation, and metabolic assessment—before any peptide therapy is considered. Patients receive structured monitoring at defined intervals, including reassessment of weight, lean tissue, cardiovascular markers, and bone density as appropriate. The concierge model provides the continuity needed to track the rapidly evolving regulatory landscape and adjust recommendations as evidence develops.

 

References 

 

Skip to content